Supreme Court extends access to abortion pill mifepristone by mail
The Supreme Court has temporarily allowed the mail-order distribution of mifepristone, a widely used abortion pill, while an appeal is pending. This decision follows requests from two drug manufacturers. (sources: cnbc, nbcnews, pbs, scotusblog, washingtonpost)
The Supreme Court has extended a temporary order permitting the mail distribution of mifepristone. This order remains in effect as the court considers an appeal regarding restrictions on the drug's access.
- Danco Laboratories and GenBioPro requested the Supreme Court to lift an appeals court ban on mail distribution of mifepristone.
- The Supreme Court's decision allows continued access to the abortion pill by mail until at least Thursday.
Why it matters
The ruling impacts access to a medication used in abortion care during ongoing legal challenges.
↓ Why this is on ModernAction
5 bills on this issue are moving right now — and the most active one is Stop Comstock Act.
H.R.2029 · 119th Congress
Stop Comstock Act
Where do you stand on this bill?
Takes about 60 seconds
About this bill
What H.R.2029 actually does
This story is about Supreme Court extends access to abortion pill by mail. This bill would The current news is about continued access to mifepristone by mail/telehealth while the Court considers limits tied (in part) to Comstock-er.
If passed, it would:
- Remove “abortion”-related language from key federal obscenity/mailing provisions and revise related import restrictions • Reduce the likelihood those provisions are used as a basis to block mailing abortion medication nationwide.
4 other bills moving on this issue
Take action on any of them individually.
This story is about Supreme Court extends access to abortion pill by mail. This bill would Potentially limit use of those statutes as a basis for restricting abortion-pill mailing nationwide.
If passed, it would
- Revise the same set of federal Comstock-related statutes in the Senate vehicle • Potentially limit use of those statutes as a basis for restricting abortion-pill mailing nationwide.
This story is about Supreme Court extends access to abortion pill by mail. This bill would abortion: Block similar FDA changes in the future (per CRS summary).
If passed, it would
- Undo the FDA’s January 2023 REMS modifications for mifepristone • Block similar FDA changes in the future (per CRS summary.
This story is about Supreme Court extends access to abortion pill by mail. This bill would Add statutory limits on FDA’s ability to relax those safeguards (including limits tied to state abortion-data submission) and restrict decla.
If passed, it would
- Nullify FDA’s January 2023 changes to mifepristone’s REMS that allowed dispensing without an in-person requirement and • Add statutory limits on FDA’s ability to relax those safeguards (including limits tied to state abortion-data.
This story is about Supreme Court extends access to abortion pill by mail. This bill would statutorily require a more restrictive mifepristone REMS framework (tied to whether the drug would be dispensed without in-per.
If passed, it would
- Require HHS to approve a mifepristone REMS “identical” to a prior version (per the bill’s official title • Put these requirements into statute rather than leaving them solely to FDA administration.
Top coverage · 1 sources